Genfit S.A.

OTCPK:GNFT.Y Stock Report

Market Cap: US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit Future Growth

Future criteria checks 4/6

Genfit is forecast to grow earnings and revenue by 25.5% and 11% per annum respectively. EPS is expected to grow by 103.2% per annum. Return on equity is forecast to be -2.5% in 3 years.

Key information

25.5%

Earnings growth rate

103.22%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate11.0%
Future return on equity-2.51%
Analyst coverage

Good

Last updated27 Feb 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

Earnings and Revenue Growth Forecasts

OTCPK:GNFT.Y - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202867-29-15-153
12/31/20271078116
12/31/2026769226
12/31/202569-39-66
6/30/202545-39-7-3N/A
3/31/202558-1946N/A
12/31/20247121516N/A
9/30/20247612-14-13N/A
6/30/20248022-43-42N/A
3/31/202457-3-50-48N/A
12/31/202334-29-58-55N/A
9/30/202332-32-55-53N/A
6/30/202329-34-52-50N/A
3/31/202328-29-62-61N/A
12/31/202226-24-73-73N/A
9/30/2022601244N/A
6/30/202294488080N/A
3/31/202290589090N/A
12/31/2021856799100N/A
9/30/202146141011N/A
6/30/20216-39-79-79N/A
3/31/20217-70-88-88N/A
12/31/20209-101-97-96N/A
9/30/202024-84-73-71N/A
6/30/202039-67-49-46N/A
3/31/202039-66-49-47N/A
12/31/201939-65-50-48N/A
9/30/201923-80-62-60N/A
6/30/20198-94-73-71N/A
3/31/20198-87N/A-64N/A
12/31/20187-80N/A-56N/A
9/30/20187-75N/AN/AN/A
6/30/20187-70N/A-56N/A
3/31/20187-63N/A-53N/A
12/31/20177-56N/A-50N/A
9/30/20177-50N/AN/AN/A
6/30/20178-44N/A-40N/A
3/31/20177-39N/A-34N/A
12/31/20167-34N/A-27N/A
9/30/20166-27N/A-23N/A
6/30/20165-21N/A-18N/A
3/31/20165-19N/A-16N/A
12/31/20154-17N/A-15N/A
9/30/20155-17N/A-17N/A
6/30/20155-17N/A-19N/A
3/31/20156-17N/A-17N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNFT.Y is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.4%).

Earnings vs Market: GNFT.Y is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GNFT.Y is expected to become profitable in the next 3 years.

Revenue vs Market: GNFT.Y's revenue (11% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: GNFT.Y's revenue (11% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GNFT.Y is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/11 13:24
End of Day Share Price 2026/03/09 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genfit S.A. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank